- Conditions
- Dysphagia, Lung Cancer, Pain, Esophagitis
- Interventions
- Manuka honey in liquid form, Manuka honey in lozenge form, Standard supportive care
- Drug
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 59
- States / cities
- Mobile, Alabama • San Francisco, California • Stanford, California + 50 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 1,055
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
- Interventions
- Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, MK-2206 with or without Trastuzumab, AMG 386 and Trastuzumab, T-DM1 and Pertuzumab, Pertuzumab and Trastuzumab, Ganetespib, ABT-888, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, Amcenestrant + Abemaciclib, Amcenestrant + Letrozole, ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, Datopotamab deruxtecan, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel, GSK 5733584, GSK 5733584 + Dostarlimab, Ivonescimab (20mg/kg Q3W)
- Drug
- Lead sponsor
- QuantumLeap Healthcare Collaborative
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2031
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 36 more
- Conditions
- Child Abuse
- Interventions
- Child Abuse Prevention Problem Solving, Active Control Group
- Behavioral
- Lead sponsor
- Boston Medical Center
- Other
- Eligibility
- Not listed
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Crohn Disease
- Interventions
- JNJ-64304500, Placebo, Adalimumab, Ustekinumab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Evansville, Indiana
- Conditions
- Pain, Depression
- Interventions
- Stepped Care, Antidepressants, Usual Care
- Behavioral · Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Wound Heal, Ulcer
- Interventions
- InnovaMatrix® AC
- Device
- Lead sponsor
- ConvaTec Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 235 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 21
- States / cities
- Fresno, California • Los Angeles, California • San Diego, California + 16 more
- Conditions
- Langerhans Cell Histiocytosis
- Interventions
- Cytarabine, Vinblastine/prednisone
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2029
- U.S. locations
- 11
- States / cities
- Palo Alto, California • San Diego, California • Minneapolis, Minnesota + 8 more
- Conditions
- Avoidant/Restrictive Food Intake Disorder
- Interventions
- Family-based Treatment for ARFID, Manualized Non-Specific Usual Care for ARFID
- Behavioral
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Placebo ELLIPTA, Nemiralisib ELLIPTA 50 µg, Nemiralisib ELLIPTA 100 µg, Nemiralisib ELLIPTA 250 µg, Nemiralisib ELLIPTA 500 µg, Nemiralisib ELLIPTA 750 µg, Albuterol (Salbutamol) MDI or nebules, Standard of care therapy
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 943 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 21
- States / cities
- Mobile, Alabama • Colorado Springs, Colorado • Daytona Beach, Florida + 17 more
- Conditions
- Epithelial Ovarian Cancer
- Interventions
- Cvac
- Biological
- Lead sponsor
- Prima BioMed Ltd
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 13
- States / cities
- Greenbrae, California • La Jolla, California • Palo Alto, California + 10 more
- Conditions
- Diabetes Mellitus, Type 2, Hypoglycemia
- Interventions
- FreeStyle Libre 2 CGM, FreeStyle Libre Pro blinded CGM, FreeStyle Precision Neo blood glucose meter
- Device
- Lead sponsor
- Palo Alto Medical Foundation
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 2
- States / cities
- Palo Alto, California • Atlanta, Georgia
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Faricimab, Sham Procedure, Anti-VEGF Therapy
- Drug · Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,036 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 85
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 75 more
- Conditions
- HIV
- Interventions
- HIV Infant Tracking System (HITSystem) 2.0, Standard of PMTCT care
- Behavioral
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Acute Lymphoblastic Leukemia, Pediatric
- Interventions
- Pegaspargase, Erwinia asparaginase, Cyclophosphamide, CYTARABINE, DASATINIB, DEXAMETHASONE, Dexrazoxane, Doxorubicin, ETOPOSIDE, HYDROCORTISONE, LEUCOVORIN CALCIUM, MERCAPTOPURINE, METHOTREXATE, NELARABINE, Vincristine
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 560 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2034
- U.S. locations
- 7
- States / cities
- Boston, Massachusetts • New Brunswick, New Jersey • Buffalo, New York + 3 more
- Conditions
- Breast Cancer, Cardiotoxicity
- Interventions
- antihypertensive medications, Blood pressure measurement, Echocardiogram, Symptom-limited cardiopulmonary exercise test, Quality of Life Measures, Biomarkers
- Other · Diagnostic Test
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
- Interventions
- Zentalis, Gemzar
- Drug
- Lead sponsor
- Brandon Huffman, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Idiopathic Thrombocytopenic Purpura
- Interventions
- Eltrombopag, Avatrombopag, Standard of care
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Watertown, South Dakota
- Conditions
- Cervical Cancer, Endometrial Cancer, Ovarian Epithelial Cancer, Ovarian Germ Cell Tumor, Uterine Sarcoma, Vulvar Cancer
- Interventions
- questionnaire administration, standard follow-up care, educational intervention
- Other · Procedure
- Lead sponsor
- New Mexico Cancer Research Alliance
- Other
- Eligibility
- 30 Years and older · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Albuquerque, New Mexico
- Conditions
- Venous Leg Ulcer, Venous Ulcer, Venous Stasis Ulcer, Venous Stasis, Wound Heal, Wounds, Venous Insufficiency of Leg, Non-healing Wound
- Interventions
- TR987 0.1% gel + Standard of Care, Standard of care
- Drug · Other
- Lead sponsor
- TR Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 312 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 33
- States / cities
- Tucson, Arizona • Castro Valley, California • Fresno, California + 27 more
- Conditions
- Prostate Cancer, Cardiovascular Diseases
- Interventions
- CV Care Program
- Behavioral
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Human Papilloma Virus, Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, HPV-Related Squamous Cell Carcinoma, HNSCC
- Interventions
- Carboplatin, Paclitaxel, Nivolumab, Radiation, Hydroxyurea Pill, 5-fluorouracil, Filgrastim Injection, Cisplatin
- Drug · Radiation
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Spondylolysis, Symptomatic Spondylolysis, Athletes
- Interventions
- Bone Stimulator, Standard of Care Spondylolysis Treatment
- Device · Other
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 16 Years to 40 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Obsessive Compulsive Disorder, Stepped Care Cognitive Behavioral Therapy
- Interventions
- Stepped Care Cognitive Behavioral Therapy, Cognitive Behavioral Therapy
- Behavioral
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- St. Petersburg, Florida
- Conditions
- Cancer, Cancer, Treatment-Related
- Interventions
- ImmunOncoTool Condition
- Behavioral
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Chicago, Illinois